Salgado M C, Caldo H, Rodrigues M C
Department of Pharmacology, School of Medicine, Ribeirão Prêto, University of São Paulo, Brazil.
Hypertension. 1992 Feb;19(2 Suppl):II251-4. doi: 10.1161/01.hyp.19.2_suppl.ii251.
Bradykinin is a potent vasodilator peptide; however, its half-life in vivo is very short because of various plasma and tissue peptidases that hydrolyze bradykinin to inactive fragments. We studied the role of kininase II (angiotensin converting enzyme) and neutral endopeptidase 24.11 (enkephalinase) in the catabolism of bradykinin in vascular tissue by determining the effect of inhibitors of kininase II (captopril) and of endopeptidase 24.11 (phosphoramidon) on the action of bradykinin on rat isolated mesenteric arteries. Because bradykinin may induce prostaglandin formation and release, we also studied the effect of a cyclooxygenase inhibitor, indomethacin, on the action of bradykinin. The mesenteric bed was isolated from rats (250-300 g) with rats under either anesthesia and was perfused with Krebs' solution (4 ml/min) containing phenylephrine (0.5-1.0 microgram/ml) to produce a mean perfusion pressure of 120-130 mm Hg. Bradykinin (2.5-40.0 ng), injected as a bolus, produced a dose-dependent decrease in perfusion pressure. In the presence of indomethacin (1.0 microgram/ml), the amplitude of the vasodilator responses to bradykinin was not significantly affected, although the duration of the responses was increased approximately two to four times. In the presence of captopril (1.0 microgram/ml), bradykinin elicited either a vasodilator or a biphasic effect. The vasodilator effect was greatly potentiated by captopril, whereas the duration of the response was unchanged when compared with control experiments. When present, the pressor responses were also dose related. In the presence of indomethacin plus captopril, bradykinin produced only a fall in perfusion pressure that lasted five to six times longer than without any treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
缓激肽是一种强效血管舒张肽;然而,由于各种血浆和组织肽酶将缓激肽水解为无活性片段,其在体内的半衰期非常短。我们通过测定缓激肽II(血管紧张素转换酶)抑制剂(卡托普利)和内肽酶24.11(脑啡肽酶)抑制剂(磷酰胺素)对缓激肽作用于大鼠离体肠系膜动脉的影响,研究了激肽酶II和中性内肽酶24.11在血管组织中缓激肽分解代谢中的作用。由于缓激肽可能诱导前列腺素的形成和释放,我们还研究了环氧化酶抑制剂吲哚美辛对缓激肽作用的影响。从体重250 - 300克的大鼠身上分离出肠系膜床,大鼠处于麻醉状态,用含有去氧肾上腺素(0.5 - 1.0微克/毫升)的克雷布斯溶液(4毫升/分钟)灌注,以使平均灌注压达到120 - 130毫米汞柱。以推注方式注射缓激肽(2.5 - 40.0纳克)会使灌注压产生剂量依赖性下降。在吲哚美辛(1.0微克/毫升)存在的情况下,缓激肽引起的血管舒张反应幅度没有受到显著影响,尽管反应持续时间增加了约两到四倍。在卡托普利(1.0微克/毫升)存在的情况下,缓激肽引发血管舒张或双相效应。卡托普利极大地增强了血管舒张效应,而与对照实验相比,反应持续时间没有变化。当出现升压反应时,也与剂量相关。在吲哚美辛加卡托普利存在的情况下,缓激肽仅使灌注压下降,且持续时间比未进行任何处理时长五到六倍。(摘要截短于250字)